INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 445m ago
HOUSE PTR44m ago
SEC 13F44m ago
ROBINHOOD CHAIN44m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Benkowitz Michael sold UTHR

PRESIDENT AND COO · UNITED THERAPEUTICS Corp · Common Stock

Side
SELL
Value
$125K
Shares
271
Price
$461.12
Executed
Jan 20, 2026
Disclosed
Jan 28, 2026
Disclosure timeline8 days from execution to publication · legal deadline 2 business days
Jan 20 executedJan 28, 2026 disclosed

UTHR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
19/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+4 / 25

    $125K reported value · 4.0% of prior position

  • Filing timing+10 / 15

    Disclosed 6 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    4 prior trades recorded in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · UTHR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$605K
    1,010 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$409K
    683 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    14
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$1.23M
    2,039 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$698K
    1,174 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$312K
    526 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    12
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Option exercise · 10b5-1 plan
    		M$1.21M
    8,300 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Option exercise · 10b5-1 plan
    		M—
    8,300 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    8
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$241K
    401 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    5
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$47K
    78 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$683K
    1,133 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$749K
    1,256 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    5
    MN
    Mesa NildaDirector
    UTHRUNITED THERAPEUTICS Corp
    Option exercise
    		M$14K
    130 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    5
    MN
    Mesa NildaDirector
    UTHRUNITED THERAPEUTICS Corp
    Option exercise
    		M—
    130 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    20
    MN
    Mesa NildaDirector
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale
    		SELL$66K
    130 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    17
    MN
    Mesa NildaDirector
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale
    		SELL$50K
    98 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    4
    EJ
    Edgemond JamesCFO AND TREASURER
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$504K
    880 sh
    		Apr 20, 2026Apr 21, 2026
    traded Apr 20, 2026
    		+1dSEC FORM 4

    Evidence

    4
    EJ
    Edgemond JamesCFO AND TREASURER
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$289K
    500 sh
    		Apr 20, 2026Apr 21, 2026
    traded Apr 20, 2026
    		+1dSEC FORM 4

    Evidence

    0
    EJ
    Edgemond JamesCFO AND TREASURER
    UTHRUNITED THERAPEUTICS Corp
    Option exercise · 10b5-1 plan
    		M—
    10.0K sh
    		Apr 20, 2026Apr 21, 2026
    traded Apr 20, 2026
    		+1dSEC FORM 4

    Evidence

    4
    EJ
    Edgemond JamesCFO AND TREASURER
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$581K
    1,010 sh
    		Apr 20, 2026Apr 21, 2026
    traded Apr 20, 2026
    		+1dSEC FORM 4

    Evidence

    1
    EJ
    Edgemond JamesCFO AND TREASURER
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$139K
    238 sh
    		Apr 20, 2026Apr 21, 2026
    traded Apr 20, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001673232-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 20, 2026
    Published
    Jan 28, 2026
    Ingested by INSIDER
    Nov 5, 04:20 UTC
    Last re-read
    Nov 5, 04:20 UTC

    Extracted facts

    Filer
    Benkowitz Michael
    Role
    PRESIDENT AND COO
    Transaction
    Open-market saleAs filed: “S”
    Asset
    UNITED THERAPEUTICS Corp
    Ticker
    UTHR
    Shares
    271
    Price per share
    $461.12
    Value
    $124,963
    Execution date (reported)
    Jan 20, 2026
    Owned after transaction
    6,524 shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    8

    Calculation

    Value = shares × reported price per share

    • Shares: 271
    • Price: $461.1183

    = $124,963

    What this establishes

    Benkowitz Michael filed this Form 4 reporting a open-market sale of UTHR on Jan 20, 2026. It became public on Jan 28, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    PRESIDENT AND COO
    Benkowitz Michaelcik:0001673232
    Issuer
    UNITED THERAPEUTICS Corpcik:0001082554

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.